Navigation Links
Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato® Loxapine) NDA
Date:10/11/2010

MOUNTAIN VIEW, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug Application (NDA) for AZ-004 (Staccato® loxapine), submitted as Adusuve™ Staccato® (loxapine) inhalation aerosol, 5 mg and 10 mg.  A CRL is issued by FDA's Center for Drug Evaluation and Research indicating that the NDA review cycle is complete and the application is not ready for approval in its present form.  AZ-004 is being developed for the rapid treatment of agitation in schizophrenia or bipolar disorder patients.

In the CRL, the FDA stated that their primary clinical safety concern was related to data from the three Phase 1 pulmonary safety studies with AZ-004.  This concern was primarily based on observed, dose-related post-dose decreases in forced expiratory volume in one second, or FEV1, a standard measure of lung function, in healthy subjects and in subjects with COPD and asthma.  The agency also noted that decreases in FEV1 were recorded in subjects who were administered device-only, placebo versions of AZ-004.  Alexza intends to meet with the FDA in the near future to discuss steps to address this FDA concern.  As Alexza has previously reported, there were no serious or severe respiratory adverse events in these trials or reported in the two Phase 3 clinical trials of AZ-004.  All respiratory symptoms that developed after treatment in the Phase 1 subjects with COPD and asthma were either self-limiting or readily managed with an inhaled bronchodilator.

The CRL also raised issues relating to the suitability of the stability studies undertaken by Alexza and certain other items relating to the agency's recently completed pre-approval manufacturing inspection. 
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014   NuAire , a manufacturer of ergonomically designed laboratory ... Koki of Japan to sell and ... . NuAire will utilize its network of sales professionals throughout ... to offer assistance in application use, product benefits and ...
(Date:1/14/2014)... VALHALLA, N.Y. , Jan. 14, 2014   Oligomerix, Inc. ... disease modifying therapeutics for Alzheimer,s disease (AD) and related ... headquarters to Valhalla, NY as ... additional laboratory space at New York Medical College. ...
(Date:1/14/2014)...   Evidera , a leading provider of evidence-based solutions ... Drug Evaluation and Research (CDER), U.S. Food and Drug ... for a patient-reported outcome (PRO) measure in drug development: ... [EXACT] for Measurement of Symptoms of Acute Bacterial Exacerbation ...
Breaking Medicine Technology:NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
(Date:7/9/2014)... (PHILADELPHIA) Researchers at the Perelman School of Medicine ... Roswell Park Cancer Institute have received an $8 million ... the effects of photodynamic light therapy (PDT) in patients ... cancer that most often manifests itself in the lining ... exposure to asbestos. The grant will fund a clinical ...
(Date:7/9/2014)... network of signals active in almost all types of ... overdrive, and may help fuel a tumour,s uncontrolled growth, ... Cancer Research, London, identified a molecular trigger responsible for ... the cellular factory that makes the building blocks cancer ... the TOR signalling pathway, called SREBP, controls the flow ...
(Date:7/9/2014)... cancer, researchers have uncovered mutations in a cell-signaling pathway ... knowledge may expand treatments for patients because drugs targeting ... are in clinical trials. , Reporting July 9 in ... (TCGA), including researchers at Washington University School of Medicine ... studied tumors from 230 patients with lung adenocarcinoma. , ...
(Date:7/9/2014)... Chase Cancer Center paint a relatively optimistic picture of ... that have spread to the chest wall or skin, ... the skin, regardless of size and whether they have ... and called "locally advanced" tumors, suggesting that they ... poor survival. Locally advanced breast cancers of this and ...
(Date:7/9/2014)... used in policing injection drug users in Russia ... , A study, conducted by researchers from ... in collaboration with St. Petersburg Pavlov State University, ... on the health outcomes of a cohort of ... , Those who were arrested by police were ...
Breaking Medicine News(10 mins):Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:BU researchers relate arrests with HIV risk environment 2
... TO LIFE , , CHICAGO, ... Maria Siemionow, MD, who performed this country,s first face transplant ... Facial transplantation plastic surgery offers great hope for those who ... "The nation,s first face transplant is another great ...
... A new U.S. study has found that being circumcised ... African American men known to have been exposed to ... clinical trials in Africa, where interventional use of adult ... in heterosexual men. The findings of the new study, ...
... , , WASHINGTON, Dec. 17 ... released A Call for Action: Enabling Healthcare Reform Using ... recommendations for the Obama Administration and 111th Congress to harness ... , , "President-elect Obama and ...
... bacteria make their home in the vertebrate gut. Though ... host, othersthe pathogensare unwelcome visitors, causing disease. , ... bacterium. It has evolved sophisticated means of growth, replication, ... body, where it is responsible for most cases of ...
... Bulletin Board: VHGI) the owners of Veriscrip(TM), the,nation,s only ... appointed Anthony Bocchichio to its Advisory Board. , ... 37 years of experience in Federal drug law,enforcement, 25 ... He served,as both Assistant Special Agent in Charge and ...
... record number of course dates for its STARCenter in 2009. ... 22 class sessions focused on pharmacy best practice in relation ... handling. , , ENGLEWOOD, Colo., ... dates for training at its STAR (Skills Training, Academics and ...
Cached Medicine News:Health News:Plastic Surgery Experts Available to Comment on Face Transplant Surgery 2Health News:Circumcision reduces the risk of HIV infection in heterosexual US men 2Health News:HIMSS Releases Health IT Blueprint for Obama Administration and Congress 2Health News:HIMSS Releases Health IT Blueprint for Obama Administration and Congress 3Health News:HIMSS Releases Health IT Blueprint for Obama Administration and Congress 4Health News:Gut instinct: Salmonella bacteria's molecular tactics to cause illness 2Health News:Gut instinct: Salmonella bacteria's molecular tactics to cause illness 3Health News:Gut instinct: Salmonella bacteria's molecular tactics to cause illness 4Health News:VirtualHealth Technologies, Inc. Appoints Former DEA Assistant Administrator to its Advisory Board 2Health News:Baxa Announces 2009 Course Dates for Its STAR Center(R) Training Facility 2Health News:Baxa Announces 2009 Course Dates for Its STAR Center(R) Training Facility 3Health News:Baxa Announces 2009 Course Dates for Its STAR Center(R) Training Facility 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: